Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» BAF-312
BAF-312
Novartis chief Jimenez touts two top PhIII drug prospects
Endpoints
Wed, 01/18/17 - 10:07 am
Novartis
Joe Jimenez
CTL-019
BAF-312
CAR-T
progressive MS
multiple sclerosis